Drugs / LANTUS insulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00511472 Background | Jul 2007 → Apr 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT02365233 Comparator | May 2013 → Dec 2016 | NAFLD1, type 2 diabetes mellitus | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-06-13 | Merck Sharp & Dohme LLC | Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus® merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lantus insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02365233 ↗ |
| Known as | LANTUS | “LANTUS” NCT00511472 ↗ |
| Modality | Protein / enzyme biologic | “Lantus insulin” NCT02365233 ↗ |